SARS-CoV-2 neutralizing antibody development strategies

Authors

BERTAN KORAY BALCIOĞLU
MELİS DENİZCİ ÖNCÜ
HASAN ÜMİT ÖZTÜRK
FATIMA YÜCEL
FİLİZ KAYA
MÜGE SERHATLI
HİVDA ÜLBEĞİ POLAT
ŞABAN TEKİN
AYLİN ÖZDEMİR BAHADIR

Abstract

In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization (WHO) described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis (the COVID-19 disease) within three months, with socioeconomic implications. No approved targeted-therapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 (ACE2) receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.

DOI

10.3906/biy-2005-91

Keywords

SARS-CoV-2, COVID-19, neutralizing antibodies, human monoclonal antibody, display technologies, human scFv, neutralizing assays, animal models

First Page

203

Last Page

214

Recommended Citation

BALCIOĞLU, BERTAN KORAY; ÖNCÜ, MELİS DENİZCİ; ÖZTÜRK, HASAN ÜMİT; YÜCEL, FATIMA; KAYA, FİLİZ; SERHATLI, MÜGE; POLAT, HİVDA ÜLBEĞİ; TEKİN, ŞABAN; and BAHADIR, AYLİN ÖZDEMİR (2020) "SARS-CoV-2 neutralizing antibody development strategies," Turkish Journal of Biology: Vol. 44: No. 7, Article 9. https://doi.org/10.3906/biy-2005-91
Available at: https://journals.tubitak.gov.tr/biology/vol44/iss7/9